{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T00:18:02Z","timestamp":1791505082368,"version":"4.3.4"},"reference-count":285,"publisher":"The Endocrine Society","issue":"1","license":[{"start":{"date-parts":[[2023,8,9]],"date-time":"2023-08-09T00:00:00Z","timestamp":1691539200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01EB028848"],"award-info":[{"award-number":["R01EB028848"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001602","name":"Science Foundation Ireland","doi-asserted-by":"publisher","award":["20\/US\/3676"],"award-info":[{"award-number":["20\/US\/3676"]}],"id":[{"id":"10.13039\/501100001602","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006662","name":"NIHR","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006662","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100018956","name":"Cambridge Biomedical Research Centre","doi-asserted-by":"publisher","award":["BRC-1215-20014"],"award-info":[{"award-number":["BRC-1215-20014"]}],"id":[{"id":"10.13039\/501100018956","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,1,4]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Primary aldosteronism (PA) is the most common cause of secondary hypertension and is associated with increased morbidity and mortality when compared with blood pressure\u2013matched cases of primary hypertension. Current limitations in patient care stem from delayed recognition of the condition, limited access to key diagnostic procedures, and lack of a definitive therapy option for nonsurgical candidates. However, several recent advances have the potential to address these barriers to optimal care. From a diagnostic perspective, machine-learning algorithms have shown promise in the prediction of PA subtypes, while the development of noninvasive alternatives to adrenal vein sampling (including molecular positron emission tomography imaging) has made accurate localization of functioning adrenal nodules possible. In parallel, more selective approaches to targeting the causative aldosterone-producing adrenal adenoma\/nodule (APA\/APN) have emerged with the advent of partial adrenalectomy or precision ablation. Additionally, the development of novel pharmacological agents may help to mitigate off-target effects of aldosterone and improve clinical efficacy and outcomes. Here, we consider how each of these innovations might change our approach to the patient with PA, to allow more tailored investigation and treatment plans, with corresponding improvement in clinical outcomes and resource utilization, for this highly prevalent disorder.<\/jats:p>","DOI":"10.1210\/endrev\/bnad026","type":"journal-article","created":{"date-parts":[[2023,8,8]],"date-time":"2023-08-08T20:33:20Z","timestamp":1691526800000},"page":"125-170","source":"Crossref","is-referenced-by-count":53,"title":["Treating Primary Aldosteronism-Induced Hypertension: Novel Approaches and Future Outlooks"],"prefix":"10.1210","volume":"45","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7266-2965","authenticated-orcid":false,"given":"Nathan","family":"Mullen","sequence":"first","affiliation":[{"name":"The Discipline of Pharmacology and Therapeutics, School of Medicine, University of Galway , Galway H91V4AY , Ireland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Curneen","sequence":"additional","affiliation":[{"name":"The Discipline of Pharmacology and Therapeutics, School of Medicine, University of Galway , Galway H91V4AY , Ireland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Padraig T","family":"Donlon","sequence":"additional","affiliation":[{"name":"The Discipline of Pharmacology and Therapeutics, School of Medicine, University of Galway , Galway H91V4AY , Ireland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Punit","family":"Prakash","sequence":"additional","affiliation":[{"name":"Department of Electrical and Computer Engineering, Kansas State University , Manhattan, KS 66506 , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9332-2524","authenticated-orcid":false,"given":"Irina","family":"Bancos","sequence":"additional","affiliation":[{"name":"Division of Endocrinology, Diabetes, Metabolism, and Nutrition, Department of Internal Medicine, Mayo Clinic , Rochester, MN 55905 , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5745-6832","authenticated-orcid":false,"given":"Mark","family":"Gurnell","sequence":"additional","affiliation":[{"name":"Wellcome-MRC Institute of Metabolic Science, University of Cambridge and NIHR Cambridge Biomedical Research Centre, Addenbrooke's Hospital , Cambridge Biomedical Campus, Cambridge CB2 0QQ , UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9325-6520","authenticated-orcid":false,"given":"Michael C","family":"Dennedy","sequence":"additional","affiliation":[{"name":"The Discipline of Pharmacology and Therapeutics, School of Medicine, University of Galway , Galway H91V4AY , Ireland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"80","published-online":{"date-parts":[[2023,8,9]]},"reference":[{"issue":"10010","key":"2024010407204523200_bnad026-B1","doi-asserted-by":"crossref","first-page":"2287","DOI":"10.1016\/S0140-6736(15)00128-2","article-title":"GBD 2013 Risk factors collaborators global, regional, and national comparative risk assessment of 79 behavioural, environmental and occupational, and metabolic risks or clusters of risks in 188 countries, 1990-2013: a systematic analysis for the global burden of disease study 2013","volume":"386","author":"Forouzanfar","year":"2015","journal-title":"Lancet"},{"issue":"5","key":"2024010407204523200_bnad026-B2","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1016\/j.ejim.2011.05.004","article-title":"Endocrine hypertension\u2014current understanding and comprehensive management review","volume":"22","author":"Sukor","year":"2011","journal-title":"Eur J Intern Med"},{"issue":"3","key":"2024010407204523200_bnad026-B3","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1161\/01.CIR.101.3.329","article-title":"Essential hypertension: part I: definition and etiology","volume":"101","author":"Carretero","year":"2000","journal-title":"Circulation"},{"issue":"7","key":"2024010407204523200_bnad026-B4","doi-asserted-by":"crossref","first-page":"2826","DOI":"10.1210\/jc.2016-1472","article-title":"Study heterogeneity and estimation of prevalence of primary aldosteronism: a systematic review and meta-regression analysis","volume":"101","author":"K\u00e4yser","year":"2016","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"2024010407204523200_bnad026-B5","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1097\/MED.0000000000000408","article-title":"Primary aldosteronism in the primary care setting","volume":"25","author":"Buffolo","year":"2018","journal-title":"Curr Opin Endocrinol Diabetes Obes"},{"issue":"11","key":"2024010407204523200_bnad026-B6","doi-asserted-by":"crossref","first-page":"2293","DOI":"10.1016\/j.jacc.2006.07.059","article-title":"A prospective study of the prevalence of primary aldosteronism in 1,125 hypertensive patients","volume":"48","author":"Rossi","year":"2006","journal-title":"J Am Coll Cardiol"},{"issue":"9","key":"2024010407204523200_bnad026-B7","doi-asserted-by":"crossref","first-page":"3266","DOI":"10.1210\/jc.2008-0104","article-title":"Case detection, diagnosis, and treatment of patients with primary aldosteronism: an endocrine society clinical practice guideline","volume":"93","author":"Funder","year":"2008","journal-title":"J Clin Endocrinol Metab"},{"issue":"8","key":"2024010407204523200_bnad026-B8","doi-asserted-by":"crossref","first-page":"408","DOI":"10.5694\/mja2.51438","article-title":"Detecting primary aldosteronism in Australian primary care: a prospective study","volume":"216","author":"Libianto","year":"2022","journal-title":"Med J Aust"},{"issue":"4","key":"2024010407204523200_bnad026-B9","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1152\/physrev.00026.2015","article-title":"Primary aldosteronism: changing definitions and new concepts of physiology and pathophysiology both inside and outside the kidney","volume":"96","author":"Stowasser","year":"2016","journal-title":"Physiol Rev"},{"issue":"2","key":"2024010407204523200_bnad026-B10","doi-asserted-by":"crossref","first-page":"101368","DOI":"10.1016\/j.beem.2019.101368","article-title":"Primary aldosteronism: treatment of the disease, and new therapeutic approaches","volume":"34","author":"Funder","year":"2020","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"issue":"7","key":"2024010407204523200_bnad026-B11","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1038\/s41371-020-0336-2","article-title":"Primary aldosteronism is a public health issue: challenges and opportunities","volume":"34","author":"Libianto","year":"2020","journal-title":"J Hum Hypertens"},{"issue":"1","key":"2024010407204523200_bnad026-B12","doi-asserted-by":"crossref","first-page":"10","DOI":"10.7326\/M20-0065","article-title":"The unrecognized prevalence of primary aldosteronism: a cross-sectional study","volume":"173","author":"Brown","year":"2020","journal-title":"Ann Intern Med"},{"issue":"1","key":"2024010407204523200_bnad026-B13","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1210\/clinem\/dgaa484","article-title":"International histopathology consensus for unilateral primary aldosteronism","volume":"106","author":"Williams","year":"2021","journal-title":"J Clin Endocrinol Metab"},{"issue":"8","key":"2024010407204523200_bnad026-B14","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1016\/j.jacc.2005.01.015","article-title":"Evidence for an increased rate of cardiovascular events in patients with primary aldosteronism","volume":"45","author":"Milliez","year":"2005","journal-title":"J Am Coll Cardiol"},{"issue":"1","key":"2024010407204523200_bnad026-B15","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/S2213-8587(17)30319-4","article-title":"Cardiovascular events and target organ damage in primary aldosteronism compared with essential hypertension: a systematic review and meta-analysis","volume":"6","author":"Monticone","year":"2018","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"9","key":"2024010407204523200_bnad026-B16","doi-asserted-by":"crossref","first-page":"5070","DOI":"10.1210\/jc.2005-0681","article-title":"Evidence for abnormal left ventricular structure and function in normotensive individuals with familial hyperaldosteronism type I","volume":"90","author":"Stowasser","year":"2005","journal-title":"J Clin Endocrinol Metab"},{"issue":"5","key":"2024010407204523200_bnad026-B17","doi-asserted-by":"crossref","first-page":"1593","DOI":"10.1210\/jc.2013-2180","article-title":"Predictors of decreasing glomerular filtration rate and prevalence of chronic kidney disease after treatment of primary aldosteronism: renal outcome of 213 cases","volume":"99","author":"Iwakura","year":"2014","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"2024010407204523200_bnad026-B18","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1161\/HYPERTENSIONAHA.118.11568","article-title":"Renal outcomes in medically and surgically treated primary aldosteronism","volume":"72","author":"Hundemer","year":"2018","journal-title":"Hypertension"},{"issue":"4","key":"2024010407204523200_bnad026-B19","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1016\/j.ecl.2019.08.002","article-title":"Primary aldosteronism diagnosis and management: a clinical approach","volume":"48","author":"Hundemer","year":"2019","journal-title":"Endocrinol Metab Clin North Am"},{"issue":"3","key":"2024010407204523200_bnad026-B20","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1161\/HYPERTENSIONAHA.117.10263","article-title":"Prevalence of cardiovascular disease and its risk factors in primary aldosteronism: a multicenter study in Japan","volume":"71","author":"Ohno","year":"2018","journal-title":"Hypertension"},{"issue":"6","key":"2024010407204523200_bnad026-B21","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1055\/s-0029-1243257","article-title":"Comorbidities in primary aldosteronism","volume":"42","author":"Quinkler","year":"2010","journal-title":"Hormone Metab Res"},{"issue":"1","key":"2024010407204523200_bnad026-B22","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.tem.2021.10.002","article-title":"Pathophysiology and histopathology of primary aldosteronism","volume":"33","author":"Williams","year":"2022","journal-title":"Trends Endocrinol Metab"},{"issue":"2","key":"2024010407204523200_bnad026-B23","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1016\/j.atherosclerosis.2011.09.008","article-title":"Plasma aldosterone levels and aldosterone-to-renin ratios are associated with endothelial dysfunction in young to middle-aged subjects","volume":"219","author":"Hannemann","year":"2011","journal-title":"Atherosclerosis"},{"issue":"24","key":"2024010407204523200_bnad026-B24","doi-asserted-by":"crossref","first-page":"2604","DOI":"10.1161\/CIRCULATIONAHA.106.634626","article-title":"High plasma aldosterone levels on admission are associated with death in patients presenting with acute ST-elevation myocardial infarction","volume":"114","author":"Beygui","year":"2006","journal-title":"Circulation"},{"issue":"5","key":"2024010407204523200_bnad026-B25","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1161\/HYPERTENSIONAHA.115.07074","article-title":"Aldosterone-induced vascular remodeling and endothelial dysfunction require functional angiotensin type 1a receptors","volume":"67","author":"Briet","year":"2016","journal-title":"Hypertension"},{"issue":"2","key":"2024010407204523200_bnad026-B26","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1093\/eurheartj\/ehr176","article-title":"Aldosterone, mortality, and acute ischaemic events in coronary artery disease patients outside the setting of acute myocardial infarction or heart failure","volume":"33","author":"Ivanes","year":"2012","journal-title":"Eur Heart J"},{"issue":"9","key":"2024010407204523200_bnad026-B27","doi-asserted-by":"crossref","first-page":"1899","DOI":"10.1161\/HYPERTENSIONAHA.122.17964","article-title":"Aldosterone as a mediator of cardiovascular damage","volume":"79","author":"Buffolo","year":"2022","journal-title":"Hypertension"},{"issue":"1","key":"2024010407204523200_bnad026-B28","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/S2213-8587(17)30367-4","article-title":"Cardiometabolic outcomes and mortality in medically treated primary aldosteronism: a retrospective cohort study","volume":"6","author":"Hundemer","year":"2018","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"8","key":"2024010407204523200_bnad026-B29","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1001\/jamacardio.2018.2003","article-title":"Incidence of atrial fibrillation and mineralocorticoid receptor activity in patients with medically and surgically treated primary aldosteronism","volume":"3","author":"Hundemer","year":"2018","journal-title":"JAMA Cardiol"},{"issue":"4","key":"2024010407204523200_bnad026-B30","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1210\/jc.2008-2116","article-title":"Cardiovascular and cerebrovascular comorbidities of hypokalemic and normokalemic primary aldosteronism: results of the German Conn's Registry","volume":"94","author":"Born-Frontsberg","year":"2009","journal-title":"J Clin Endocrinol Metab"},{"issue":"6","key":"2024010407204523200_bnad026-B31","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1055\/s-0029-1246189","article-title":"Is primary aldosteronism associated with diabetes mellitus? Results of the German Conn's Registry","volume":"42","author":"Reincke","year":"2010","journal-title":"Horm Metab Res"},{"issue":"3","key":"2024010407204523200_bnad026-B32","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1210\/jc.2008-1851","article-title":"Risk factors associated with a low glomerular filtration rate in primary aldosteronism","volume":"94","author":"Reincke","year":"2009","journal-title":"J Clin Endocrinol Metab"},{"issue":"5","key":"2024010407204523200_bnad026-B33","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1007\/s11906-010-0134-2","article-title":"Prevalence and diagnosis of primary aldosteronism","volume":"12","author":"Rossi","year":"2010","journal-title":"Curr Hypertens Rep"},{"issue":"14","key":"2024010407204523200_bnad026-B34","doi-asserted-by":"crossref","first-page":"1811","DOI":"10.1016\/j.jacc.2017.01.052","article-title":"Prevalence and clinical manifestations of primary aldosteronism encountered in primary care practice","volume":"69","author":"Monticone","year":"2017","journal-title":"J Am Coll Cardiol"},{"issue":"10","key":"2024010407204523200_bnad026-B35","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1038\/s41574-020-0382-4","article-title":"Pathogenesis and treatment of primary aldosteronism","volume":"16","author":"Zennaro","year":"2020","journal-title":"Nat Rev Endocrinol"},{"issue":"5","key":"2024010407204523200_bnad026-B36","doi-asserted-by":"crossref","first-page":"1889","DOI":"10.1210\/jc.2015-4061","article-title":"The management of primary aldosteronism: case detection, diagnosis, and treatment: an Endocrine Society clinical practice guideline","volume":"101","author":"Funder","year":"2016","journal-title":"J Clin Endocrinol Metab"},{"issue":"19","key":"2024010407204523200_bnad026-B37","doi-asserted-by":"crossref","first-page":"e127","DOI":"10.1016\/j.jacc.2017.11.006","article-title":"2017 ACC\/AHA\/AAPA\/ABC\/ACPM\/AGS\/APhA\/ASH\/ASPC\/NMA\/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: a report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines","volume":"71","author":"Whelton","year":"2018","journal-title":"J Am Coll Cardiol"},{"issue":"33","key":"2024010407204523200_bnad026-B38","doi-asserted-by":"crossref","first-page":"3021","DOI":"10.1093\/eurheartj\/ehy339","article-title":"2018 ESC\/ESH guidelines for the management of arterial hypertension: the task force for the management of arterial hypertension of the European Society of Cardiology (ESC) and the European Society of Hypertension (ESH)","volume":"39","author":"Williams","year":"2018","journal-title":"Eur Heart J"},{"key":"2024010407204523200_bnad026-B39","year":"2019"},{"issue":"42","key":"2024010407204523200_bnad026-B40","doi-asserted-by":"crossref","first-page":"3456","DOI":"10.1093\/eurheartj\/ehz681","article-title":"The 2018 ESC\/ESH hypertension guideline and the 2019 NICE hypertension guideline, how and why they differ","volume":"40","author":"McCormack","year":"2019","journal-title":"Eur Heart J"},{"issue":"1","key":"2024010407204523200_bnad026-B41","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1161\/HYPERTENSIONAHA.121.18118","article-title":"Screening rates for primary aldosteronism among individuals with hypertension plus hypokalemia: a population-based retrospective cohort study","volume":"79","author":"Hundemer","year":"2022","journal-title":"Hypertension"},{"issue":"11","key":"2024010407204523200_bnad026-B42","doi-asserted-by":"crossref","first-page":"2253","DOI":"10.1097\/HJH.0000000000001088","article-title":"Guidelines for primary aldosteronism: uptake by primary care physicians in Europe","volume":"34","author":"Mulatero","year":"2016","journal-title":"J Hypertens"},{"issue":"12","key":"2024010407204523200_bnad026-B43","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1055\/a-1938-4242","article-title":"Prevalence of primary aldosteronism in newly diagnosed hypertensive patients in primary care","volume":"130","author":"Asbach","year":"2022","journal-title":"Exp Clin Endocrinol Diabetes"},{"issue":"6","key":"2024010407204523200_bnad026-B44","doi-asserted-by":"crossref","first-page":"e061671","DOI":"10.1136\/bmjopen-2022-061671","article-title":"\u2018I can\u2019t understand why others don\u2019t screen more\u2019: a qualitative study exploring why Australian general practitioners screen for primary aldosteronism","volume":"12","author":"Nainani","year":"2022","journal-title":"BMJ Open"},{"issue":"4","key":"2024010407204523200_bnad026-B45","doi-asserted-by":"crossref","first-page":"322","DOI":"10.25122\/jml-2019-0072","article-title":"Topical diagnosis and determination of the primary hyperaldosteronism variant","volume":"12","author":"Shidlovskyi","year":"2019","journal-title":"J Med Life"},{"issue":"2","key":"2024010407204523200_bnad026-B46","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1111\/joim.12831","article-title":"Diagnosis and treatment of primary aldosteronism: practical clinical perspectives","volume":"285","author":"Young","year":"2019","journal-title":"J Intern Med"},{"issue":"1","key":"2024010407204523200_bnad026-B47","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1586\/erc.10.171","article-title":"Hypertension in aging patients","volume":"9","author":"Logan","year":"2011","journal-title":"Expert Rev Cardiovasc Ther"},{"issue":"3","key":"2024010407204523200_bnad026-B48","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1530\/EJE-21-0338","article-title":"Somatic mutations in adrenals from patients with primary aldosteronism not cured after adrenalectomy suggest common pathogenic mechanisms between unilateral and bilateral disease","volume":"185","author":"Hacini","year":"2021","journal-title":"Eur J Endocrinol"},{"issue":"9","key":"2024010407204523200_bnad026-B49","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1016\/S2213-8587(17)30135-3","article-title":"Outcomes after adrenalectomy for unilateral primary aldosteronism: an international consensus on outcome measures and analysis of remission rates in an international cohort","volume":"5","author":"Williams","year":"2017","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"6","key":"2024010407204523200_bnad026-B50","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1210\/er.2018-00139","article-title":"The expanding spectrum of primary aldosteronism: implications for diagnosis, pathogenesis, and treatment","volume":"39","author":"Vaidya","year":"2018","journal-title":"Endocr Rev"},{"issue":"9","key":"2024010407204523200_bnad026-B51","doi-asserted-by":"crossref","first-page":"630","DOI":"10.7326\/M17-0882","article-title":"The spectrum of subclinical primary aldosteronism and incident hypertension: a cohort study","volume":"167","author":"Brown","year":"2017","journal-title":"Ann Intern Med"},{"issue":"11","key":"2024010407204523200_bnad026-B52","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1038\/s41574-022-00730-2","article-title":"Primary aldosteronism\u2014a multidimensional syndrome","volume":"18","author":"Turcu","year":"2022","journal-title":"Nat Rev Endocrinol"},{"issue":"12","key":"2024010407204523200_bnad026-B53","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1093\/ajh\/hpac079","article-title":"Primary aldosteronism: state-of-the-art review","volume":"35","author":"Vaidya","year":"2022","journal-title":"Am J Hypertens"},{"issue":"7","key":"2024010407204523200_bnad026-B54","doi-asserted-by":"crossref","first-page":"e13353","DOI":"10.1111\/ijcp.13353","article-title":"The aldosterone to renin ratio in the diagnosis of primary aldosteronism: promises and challenges","volume":"73","author":"O'Shea","year":"2019","journal-title":"Int J Clin Pract"},{"issue":"3","key":"2024010407204523200_bnad026-B55","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1161\/HYPERTENSIONAHA.120.16429","article-title":"Intraindividual variability of aldosterone concentrations in primary aldosteronism: implications for case detection","volume":"77","author":"Yozamp","year":"2021","journal-title":"Hypertension"},{"issue":"5","key":"2024010407204523200_bnad026-B56","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1111\/j.1365-2265.2007.02775.x","article-title":"Primary aldosteronism: renaissance of a syndrome","volume":"66","author":"Young","year":"2007","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"2","key":"2024010407204523200_bnad026-B57","doi-asserted-by":"crossref","first-page":"E340","DOI":"10.1210\/jc.2010-1355","article-title":"Are women more at risk of false-positive primary aldosteronism screening and unnecessary suppression testing than men?","volume":"96","author":"Ahmed","year":"2011","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"2024010407204523200_bnad026-B58","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1055\/s-0031-1295460","article-title":"Factors affecting the aldosterone\/renin ratio","volume":"44","author":"Stowasser","year":"2012","journal-title":"Hormone Metab Res"},{"issue":"3","key":"2024010407204523200_bnad026-B59","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1111\/cen.12882","article-title":"\u0392-blocker withdrawal is preferable for accurate interpretation of the aldosterone-renin ratio in chronically treated hypertension","volume":"84","author":"Browne","year":"2016","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"2","key":"2024010407204523200_bnad026-B60","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1097\/HJH.0000000000000775","article-title":"A cross-sectional study of the effects of \u03b2-blocker therapy on the interpretation of the aldosterone\/renin ratio: can dosing regimen predict effect?","volume":"34","author":"Griffin","year":"2016","journal-title":"J Hypertens"},{"issue":"2","key":"2024010407204523200_bnad026-B61","first-page":"39","article-title":"Laboratory investigation of primary aldosteronism","volume":"31","author":"Stowasser","year":"2010","journal-title":"Clin Biochem Rev"},{"issue":"11","key":"2024010407204523200_bnad026-B62","doi-asserted-by":"crossref","first-page":"3989","DOI":"10.1210\/jc.2016-1963","article-title":"Dietary sodium restriction increases the risk of misinterpreting mild cases of primary aldosteronism","volume":"101","author":"Baudrand","year":"2016","journal-title":"J Clin Endocrinol Metab"},{"issue":"8","key":"2024010407204523200_bnad026-B63","doi-asserted-by":"crossref","first-page":"1835","DOI":"10.1161\/HYPERTENSIONAHA.122.19377","article-title":"Performance of confirmatory tests for diagnosing primary aldosteronism: a systematic review and meta-analysis","volume":"79","author":"Leung","year":"2022","journal-title":"Hypertension"},{"issue":"1","key":"2024010407204523200_bnad026-B64","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1186\/s42155-021-00220-y","article-title":"Adrenal vein sampling: technique and protocol, a systematic review","volume":"4","author":"Quencer","year":"2021","journal-title":"CVIR Endovascular"},{"issue":"12","key":"2024010407204523200_bnad026-B65","doi-asserted-by":"crossref","first-page":"e038489","DOI":"10.1136\/bmjopen-2020-038489","article-title":"Diagnostic accuracy of adrenal imaging for subtype diagnosis in primary aldosteronism: systematic review and meta-analysis","volume":"10","author":"Zhou","year":"2020","journal-title":"BMJ Open"},{"issue":"6","key":"2024010407204523200_bnad026-B66","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1111\/cen.13442","article-title":"Discordance between imaging and immunohistochemistry in unilateral primary aldosteronism","volume":"87","author":"Nanba","year":"2017","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"12","key":"2024010407204523200_bnad026-B67","doi-asserted-by":"crossref","first-page":"1942","DOI":"10.1038\/s41440-019-0310-y","article-title":"Primary aldosteronism subtype discordance between computed tomography and adrenal venous sampling","volume":"42","author":"Aono","year":"2019","journal-title":"Hypertens Res"},{"issue":"9","key":"2024010407204523200_bnad026-B68","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1016\/S2213-8587(16)30100-0","article-title":"Adrenal vein sampling versus CT scan to determine treatment in primary aldosteronism: an outcome-based randomised diagnostic trial","volume":"4","author":"Dekkers","year":"2016","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"12","key":"2024010407204523200_bnad026-B69","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1055\/s-0043-120524","article-title":"The SPARTACUS trial: controversies and unresolved issues","volume":"49","author":"Beuschlein","year":"2017","journal-title":"Hormone Metab Res"},{"issue":"3","key":"2024010407204523200_bnad026-B70","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1161\/HYPERTENSIONAHA.116.08820","article-title":"Adrenal venous sampling versus computed tomographic scan to determine treatment in primary aldosteronism (the SPARTACUS trial)","volume":"69","author":"Rossi","year":"2017","journal-title":"Hypertension"},{"issue":"12","key":"2024010407204523200_bnad026-B71","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1016\/S2213-8587(21)00210-2","article-title":"Diagnosis and treatment of primary aldosteronism","volume":"9","author":"Reincke","year":"2021","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"4","key":"2024010407204523200_bnad026-B72","doi-asserted-by":"crossref","first-page":"774","DOI":"10.3803\/EnM.2020.404","article-title":"Minimally invasive adrenal surgery","volume":"35","author":"Kwak","year":"2020","journal-title":"Endocrinol Metab"},{"issue":"2","key":"2024010407204523200_bnad026-B73","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1007\/s13304-017-0441-0","article-title":"Adrenalectomy: indications and options for treatment","volume":"69","author":"Alemanno","year":"2017","journal-title":"Updates Surg"},{"issue":"1","key":"2024010407204523200_bnad026-B74","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1210\/jc.2011-1537","article-title":"Evaluation of the sensitivity and specificity of 11C-metomidate positron emission tomography (PET)-CT for lateralizing aldosterone secretion by Conn's adenomas","volume":"97","author":"Burton","year":"2012","journal-title":"J Clin Endocrinol Metab"},{"issue":"5","key":"2024010407204523200_bnad026-B75","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1111\/cen.13942","article-title":"11C-Metomidate PET\/CT is a useful adjunct for lateralization of primary aldosteronism in routine clinical practice","volume":"90","author":"O'Shea","year":"2019","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"1","key":"2024010407204523200_bnad026-B76","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.urology.2012.08.059","article-title":"Retroperitoneoscopic adrenalectomy: comparison of retrograde and antegrade approach among a series of 279 cases","volume":"81","author":"Huyghe","year":"2013","journal-title":"Urology"},{"issue":"11","key":"2024010407204523200_bnad026-B77","doi-asserted-by":"crossref","first-page":"5658","DOI":"10.1210\/jc.2019-00996","article-title":"Adrenal insufficiency after unilateral adrenalectomy in primary aldosteronism: long-term outcome and clinical impact","volume":"104","author":"Heinrich","year":"2019","journal-title":"J Clin Endocrinol Metab"},{"key":"2024010407204523200_bnad026-B78","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/j.ijscr.2015.01.013","article-title":"Aldosterone deficiency after unilateral adrenalectomy for Conn's syndrome: a case report and literature review","volume":"7","author":"Yorke","year":"2015","journal-title":"Int J Surg Case Rep"},{"issue":"1","key":"2024010407204523200_bnad026-B79","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.surg.2017.07.034","article-title":"Contralateral suppression of aldosterone at adrenal venous sampling predicts hyperkalemia following adrenalectomy for primary aldosteronism","volume":"163","author":"Shariq","year":"2018","journal-title":"Surgery"},{"issue":"7","key":"2024010407204523200_bnad026-B80","doi-asserted-by":"crossref","first-page":"2437","DOI":"10.1210\/jc.2008-2803","article-title":"Role of unilateral adrenalectomy in bilateral primary aldosteronism: a 22-year single center experience","volume":"94","author":"Sukor","year":"2009","journal-title":"J Clin Endocrinol Metab"},{"issue":"11","key":"2024010407204523200_bnad026-B81","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1016\/S2213-8587(22)00253-4","article-title":"Adrenal surgery for bilateral primary aldosteronism: an international retrospective cohort study","volume":"10","author":"Williams","year":"2022","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"2","key":"2024010407204523200_bnad026-B82","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1007\/s00268-022-06780-x","article-title":"Unilateral adrenalectomy for primary aldosteronism due to bilateral adrenal disease can result in resolution of hypokalemia and amelioration of hypertension","volume":"47","author":"Szabo Yamashita","year":"2023","journal-title":"World J Surg"},{"issue":"3","key":"2024010407204523200_bnad026-B83","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1007\/s42000-020-00202-0","article-title":"Adrenal-sparing surgery: current concepts on a theme from the past","volume":"19","author":"Perysinakis","year":"2020","journal-title":"Hormones"},{"issue":"3","key":"2024010407204523200_bnad026-B84","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1007\/s11255-018-02070-5","article-title":"Organ-sparing procedures in GU cancer: part 1\u2014organ-sparing procedures in renal and adrenal tumors: a systematic review","volume":"51","author":"Seyam","year":"2019","journal-title":"Int Urol Nephrol"},{"issue":"6","key":"2024010407204523200_bnad026-B85","doi-asserted-by":"crossref","first-page":"R185","DOI":"10.1530\/EJE-20-0863","article-title":"Management of endocrine disease: the role of surgical adrenalectomy in primary aldosteronism","volume":"183","author":"Hundemer","year":"2020","journal-title":"Eur J Endocrinol"},{"issue":"1","key":"2024010407204523200_bnad026-B86","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1080\/02656736.2019.1650205","article-title":"Using microwave thermal ablation to develop a subtotal, cortical-sparing approach to the management of primary aldosteronism","volume":"36","author":"Donlon","year":"2019","journal-title":"Int J Hyperthermia"},{"issue":"11","key":"2024010407204523200_bnad026-B87","doi-asserted-by":"crossref","first-page":"1919","DOI":"10.1093\/clinchem\/48.11.1919","article-title":"Screening for primary aldosteronism: implications of an increased plasma aldosterone\/renin ratio","volume":"48","author":"Schwartz","year":"2002","journal-title":"Clin Chem"},{"issue":"3","key":"2024010407204523200_bnad026-B88","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1161\/HYPERTENSIONAHA.120.16429","article-title":"Intraindividual variability of aldosterone concentrations in primary aldosteronism","volume":"77","author":"Yozamp","year":"2021","journal-title":"Hypertension"},{"issue":"12","key":"2024010407204523200_bnad026-B89","doi-asserted-by":"crossref","first-page":"3771","DOI":"10.1210\/clinem\/dgaa606","article-title":"Evolution of the primary aldosteronism syndrome: updating the approach","volume":"105","author":"Vaidya","year":"2020","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"2024010407204523200_bnad026-B90","doi-asserted-by":"crossref","first-page":"255","DOI":"10.4103\/1947-2714.110426","article-title":"Errors in potassium measurement: a laboratory perspective for the clinician","volume":"5","author":"Asirvatham","year":"2013","journal-title":"N Am J Med Sci"},{"issue":"6","key":"2024010407204523200_bnad026-B91","doi-asserted-by":"crossref","first-page":"229","DOI":"10.3390\/metabo10060229","article-title":"Recommendations and best practices for standardizing the pre-analytical processing of blood and urine samples in metabolomics","volume":"10","author":"Gonz\u00e1lez-Dom\u00ednguez","year":"2020","journal-title":"Metabolites"},{"issue":"12","key":"2024010407204523200_bnad026-B92","doi-asserted-by":"crossref","first-page":"3775","DOI":"10.1210\/jc.2011-1565","article-title":"Urine steroid metabolomics as a biomarker tool for detecting malignancy in adrenal tumors","volume":"96","author":"Arlt","year":"2011","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"2024010407204523200_bnad026-B93","doi-asserted-by":"crossref","first-page":"e307","DOI":"10.1210\/clinem\/dgz141","article-title":"Urine steroid metabolomics as a novel tool for detection of recurrent adrenocortical carcinoma","volume":"105","author":"Chortis","year":"2020","journal-title":"J Clin Endocrinol Metab"},{"issue":"12","key":"2024010407204523200_bnad026-B94","doi-asserted-by":"crossref","first-page":"1929","DOI":"10.1515\/cclm-2022-0470","article-title":"Integration of artificial intelligence and plasma steroidomics with laboratory information management systems: application to primary aldosteronism","volume":"60","author":"Constantinescu","year":"2022","journal-title":"Clin Chem Lab Med"},{"issue":"4","key":"2024010407204523200_bnad026-B95","doi-asserted-by":"crossref","first-page":"e1111","DOI":"10.1210\/clinem\/dgaa954","article-title":"Targeted metabolomics as a tool in discriminating endocrine from primary hypertension","volume":"106","author":"Erlic","year":"2021","journal-title":"J Clin Endocrinol Metab"},{"issue":"5","key":"2024010407204523200_bnad026-B96","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.3803\/EnM.2021.1149","article-title":"Metabolic subtyping of adrenal tumors: prospective multi-center cohort study in Korea","volume":"36","author":"Ku","year":"2021","journal-title":"Endocrinol Metab"},{"issue":"1","key":"2024010407204523200_bnad026-B97","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41598-021-88712-8","article-title":"Machine learning based models for prediction of subtype diagnosis of primary aldosteronism using blood test","volume":"11","author":"Kaneko","year":"2021","journal-title":"Sci Rep"},{"issue":"9","key":"2024010407204523200_bnad026-B98","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1507\/endocrj.EJ11-0133","article-title":"Guidelines for the diagnosis and treatment of primary aldosteronism-the Japan endocrine society 2009","volume":"58","author":"Nishikawa","year":"2011","journal-title":"Endocr J"},{"issue":"4","key":"2024010407204523200_bnad026-B99","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1038\/hr.2014.20","article-title":"The Japanese society of hypertension guidelines for the management of hypertension (JSH 2014)","volume":"37","author":"Shimamoto","year":"2014","journal-title":"Hypertens Res"},{"issue":"1","key":"2024010407204523200_bnad026-B100","doi-asserted-by":"crossref","first-page":"e19739","DOI":"10.2196\/19739","article-title":"An application of machine learning to etiological diagnosis of secondary hypertension: retrospective study using electronic medical records","volume":"9","author":"Diao","year":"2021","journal-title":"JMIR Med Inform"},{"issue":"4","key":"2024010407204523200_bnad026-B101","doi-asserted-by":"crossref","first-page":"e1708","DOI":"10.1210\/clinem\/dgaa974","article-title":"Development of a prediction score to avoid confirmatory testing in patients with suspected primary aldosteronism","volume":"106","author":"Burrello","year":"2021","journal-title":"J Clin Endocrinol Metab"},{"issue":"6","key":"2024010407204523200_bnad026-B102","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1530\/EJE-20-0656","article-title":"Prediction of hyperaldosteronism subtypes when adrenal vein sampling is unilaterally successful","volume":"183","author":"Burrello","year":"2020","journal-title":"Eur J Endocrinol"},{"issue":"9","key":"2024010407204523200_bnad026-B103","doi-asserted-by":"crossref","first-page":"e2016209","DOI":"10.1001\/jamanetworkopen.2020.16209","article-title":"Use of steroid profiling combined with machine learning for identification and subtype classification in primary aldosteronism","volume":"3","author":"Eisenhofer","year":"2020","journal-title":"JAMA Network Open"},{"issue":"11","key":"2024010407204523200_bnad026-B104","doi-asserted-by":"crossref","first-page":"e012799","DOI":"10.1136\/bmjopen-2016-012799","article-title":"STARD 2015 Guidelines for reporting diagnostic accuracy studies: explanation and elaboration","volume":"6","author":"Cohen","year":"2016","journal-title":"BMJ Open"},{"issue":"6","key":"2024010407204523200_bnad026-B105","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.1210\/er.2018-00262","article-title":"Steroid metabolome analysis in disorders of adrenal steroid biosynthesis and metabolism","volume":"40","author":"Storbeck","year":"2019","journal-title":"Endocr Rev"},{"issue":"8","key":"2024010407204523200_bnad026-B106","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1210\/js.2018-00135","article-title":"GC\/MS in recent years has defined the normal and clinically disordered steroidome: will it soon be surpassed by LC\/tandem MS in this role?","volume":"2","author":"Shackleton","year":"2018","journal-title":"J Endocr Soc"},{"issue":"1","key":"2024010407204523200_bnad026-B107","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1002\/mas.20107","article-title":"Mass spectrometry in sports drug testing: structure characterization and analytical assays","volume":"26","author":"Thevis","year":"2007","journal-title":"Mass Spectrom Rev"},{"issue":"9","key":"2024010407204523200_bnad026-B108","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1016\/S2213-8587(20)30218-7","article-title":"Urine steroid metabolomics for the differential diagnosis of adrenal incidentalomas in the EURINE-ACT study: a prospective test validation study","volume":"8","author":"Bancos","year":"2020","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"8","key":"2024010407204523200_bnad026-B109","doi-asserted-by":"crossref","first-page":"e93136","DOI":"10.1172\/jci.insight.93136","article-title":"Steroid metabolome analysis reveals prevalent glucocorticoid excess in primary aldosteronism","volume":"2","author":"Arlt","year":"2017","journal-title":"JCI Insight"},{"issue":"7","key":"2024010407204523200_bnad026-B110","doi-asserted-by":"crossref","first-page":"741","DOI":"10.3390\/biomedicines9070741","article-title":"Diagnostic accuracy of dehydroepiandrosterone sulfate and corticotropin in autonomous cortisol secretion","volume":"9","author":"Carafone","year":"2021","journal-title":"Biomedicines"},{"issue":"3","key":"2024010407204523200_bnad026-B111","first-page":"786","article-title":"Low DHEAS: a sensitive and specific test for the detection of subclinical hypercortisolism in adrenal incidentalomas","volume":"102","author":"Dennedy","year":"2017","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"2024010407204523200_bnad026-B112","doi-asserted-by":"crossref","first-page":"e1181","DOI":"10.1210\/clinem\/dgab751","article-title":"Plasma steroid profiling in patients with adrenal incidentaloma","volume":"107","author":"Berke","year":"2021","journal-title":"J Clin Endocrinol Metab"},{"issue":"5","key":"2024010407204523200_bnad026-B113","doi-asserted-by":"crossref","first-page":"1595","DOI":"10.1161\/HYPERTENSIONAHA.121.17444","article-title":"Clinical score and machine learning-based model to predict diagnosis of primary aldosteronism in arterial hypertension","volume":"78","author":"Buffolo","year":"2021","journal-title":"Hypertension"},{"issue":"7","key":"2024010407204523200_bnad026-B114","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.1210\/js.2019-00131","article-title":"Lateralizing asymmetry of adrenal imaging and adrenal vein sampling in patients with primary aldosteronism","volume":"3","author":"Wada","year":"2019","journal-title":"J Endocr Soc"},{"issue":"39","key":"2024010407204523200_bnad026-B115","doi-asserted-by":"crossref","first-page":"e4986","DOI":"10.1097\/MD.0000000000004986","article-title":"Comparison between adrenal venous sampling and computed tomography in the diagnosis of primary aldosteronism and in the guidance of adrenalectomy","volume":"95","author":"Zhu","year":"2016","journal-title":"Medicine (Baltimore)"},{"issue":"3","key":"2024010407204523200_bnad026-B116","first-page":"1066","article-title":"Comparison of adrenal vein sampling and computed tomography in the differentiation of primary aldosteronism","volume":"86","author":"Magill","year":"2001","journal-title":"J Clin Endocrinol Metab"},{"issue":"5","key":"2024010407204523200_bnad026-B117","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1111\/cen.13582","article-title":"Accuracy of adrenal computed tomography in predicting the unilateral subtype in young patients with hypokalaemia and elevation of aldosterone in primary aldosteronism","volume":"88","author":"Umakoshi","year":"2018","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"5","key":"2024010407204523200_bnad026-B118","doi-asserted-by":"crossref","first-page":"e2087","DOI":"10.1210\/clinem\/dgab047","article-title":"Adrenal venous sampling in young patients with primary aldosteronism. Extravagance or irreplaceable?","volume":"106","author":"Gkaniatsa","year":"2021","journal-title":"J Clin Endocrinol Metab"},{"key":"2024010407204523200_bnad026-B119","article-title":"Discordant imaging-adrenal vein sampling in almost half of patients with primary aldosteronism and a unilateral adrenal adenoma","author":"Kaur","journal-title":"Intern Med J"},{"issue":"4","key":"2024010407204523200_bnad026-B120","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1016\/j.ecl.2019.08.012","article-title":"Adrenal venous sampling: where do we stand?","volume":"48","author":"Rossi","year":"2019","journal-title":"Endocrinol Metab Clin North Am"},{"issue":"11","key":"2024010407204523200_bnad026-B121","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1136\/jclinpath-2017-204423","article-title":"Adrenal venous sampling for primary aldosteronism: laboratory medicine best practice","volume":"70","author":"Kline","year":"2017","journal-title":"J Clin Pathol"},{"issue":"1","key":"2024010407204523200_bnad026-B122","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1161\/HYPERTENSIONAHA.117.09295","article-title":"Adrenal vein sampling is the preferred method to select patients with primary aldosteronism for adrenalectomy: pro side of the argument","volume":"71","author":"Rossi","year":"2018","journal-title":"Hypertension"},{"issue":"4","key":"2024010407204523200_bnad026-B123","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1210\/clinem\/dgaa952","article-title":"Approach to the patient with primary aldosteronism: utility and limitations of adrenal vein sampling","volume":"106","author":"Turcu","year":"2021","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"2024010407204523200_bnad026-B124","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1530\/EJE-18-0328","article-title":"Radiation exposure of adrenal vein sampling: a German multicenter study","volume":"179","author":"Fuss","year":"2018","journal-title":"Eur J Endocrinol"},{"issue":"9","key":"2024010407204523200_bnad026-B125","first-page":"996","article-title":"Learning curve of adrenal vein sampling","volume":"46","author":"Lin","year":"2021","journal-title":"Zhong Nan Da Xue Xue Bao Yi Xue Ban"},{"issue":"2","key":"2024010407204523200_bnad026-B126","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1007\/s12020-022-03122-8","article-title":"Adrenal venous sampling in primary aldosteronism: experience of a Spanish multicentric study (results from the SPAIN-ALDO register)","volume":"78","author":"Araujo-Castro","year":"2022","journal-title":"Endocrine"},{"issue":"5","key":"2024010407204523200_bnad026-B127","doi-asserted-by":"crossref","first-page":"1606","DOI":"10.1210\/jc.2011-2830","article-title":"The adrenal vein sampling international study (AVIS) for identifying the major subtypes of primary aldosteronism","volume":"97","author":"Rossi","year":"2012","journal-title":"J Clin Endocrinol"},{"issue":"1","key":"2024010407204523200_bnad026-B128","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1161\/HYPERTENSIONAHA.113.02097","article-title":"An expert consensus statement on use of adrenal vein sampling for the subtyping of primary aldosteronism","volume":"63","author":"Rossi","year":"2014","journal-title":"Hypertension"},{"issue":"1","key":"2024010407204523200_bnad026-B129","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1161\/HYPERTENSIONAHA.117.09294","article-title":"Adrenal vein sampling is the preferred method to select patients with primary aldosteronism for adrenalectomy: con side of the argument","volume":"71","author":"Deinum","year":"2018","journal-title":"Hypertension"},{"issue":"6","key":"2024010407204523200_bnad026-B130","doi-asserted-by":"crossref","first-page":"2042","DOI":"10.1210\/clinem\/dgz017","article-title":"Subtyping of primary aldosteronism in the AVIS-2 study: assessment of selectivity and lateralization","volume":"105","author":"Rossitto","year":"2020","journal-title":"J Clin Endocrinol Metab"},{"issue":"5","key":"2024010407204523200_bnad026-B131","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1530\/EJE-21-0541","article-title":"Influence of cortisol cosecretion on non-ACTH-stimulated adrenal venous sampling in primary aldosteronism: a retrospective cohort study","volume":"187","author":"Heinrich","year":"2022","journal-title":"Eur J Endocrinol"},{"key":"2024010407204523200_bnad026-B132","doi-asserted-by":"crossref","first-page":"816754","DOI":"10.3389\/fendo.2022.816754","article-title":"Case report: primary aldosteronism due to bilateral aldosterone-producing micronodules with HISTALDO classical and contralateral non-classical pathology","volume":"13","author":"Chen","year":"2022","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"4","key":"2024010407204523200_bnad026-B133","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1530\/EJE-14-1161","article-title":"Is there a role for segmental adrenal venous sampling and adrenal sparing surgery in patients with primary aldosteronism?","volume":"173","author":"Satoh","year":"2015","journal-title":"Eur J Endocrinol"},{"key":"2024010407204523200_bnad026-B134","first-page":"55716","article-title":"A novel method: super-selective adrenal venous sampling","volume":"127","author":"Makita","year":"2017","journal-title":"J Vis Exp"},{"issue":"3","key":"2024010407204523200_bnad026-B135","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1161\/HYPERTENSIONAHA.119.14341","article-title":"Precise mapping of intra-adrenal aldosterone activities provides a novel surgical strategy for primary aldosteronism","volume":"76","author":"Kitamoto","year":"2020","journal-title":"Hypertension"},{"issue":"6","key":"2024010407204523200_bnad026-B136","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1038\/jhh.2015.100","article-title":"A case of bilateral aldosterone-producing adenomas differentiated by segmental adrenal venous sampling for bilateral adrenal sparing surgery","volume":"30","author":"Morimoto","year":"2016","journal-title":"J Hum Hypertens"},{"issue":"1","key":"2024010407204523200_bnad026-B137","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1148\/radiol.2015142159","article-title":"Intra-adrenal aldosterone secretion: segmental adrenal venous sampling for localization","volume":"278","author":"Satani","year":"2016","journal-title":"Radiology"},{"issue":"2","key":"2024010407204523200_bnad026-B138","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1111\/j.1365-2265.2009.03714.x","article-title":"Adrenal vein sampling for primary aldosteronism: time for a reality check","volume":"72","author":"Stewart","year":"2010","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"6","key":"2024010407204523200_bnad026-B139","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1097\/HJH.0000000000003132","article-title":"11C-Metomidate PET-CT versus adrenal vein sampling to subtype primary aldosteronism: a prospective clinical trial","volume":"40","author":"Puar","year":"2022","journal-title":"J Hypertens"},{"issue":"6","key":"2024010407204523200_bnad026-B140","doi-asserted-by":"crossref","first-page":"2358","DOI":"10.1210\/jc.2008-0050","article-title":"[123I] Iodometomidate for molecular imaging of adrenocortical cytochrome P450 family 11B enzymes","volume":"93","author":"Hahner","year":"2008","journal-title":"J Clin Endocrinol Metab"},{"issue":"6","key":"2024010407204523200_bnad026-B141","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1007\/s12672-011-0093-3","article-title":"Metomidate-based imaging of adrenal masses","volume":"2","author":"Hahner","year":"2011","journal-title":"Horm Cancer"},{"issue":"3","key":"2024010407204523200_bnad026-B142","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1007\/s12020-020-02474-3","article-title":"11C-metomidate PET in the diagnosis of adrenal masses and primary aldosteronism: a review of the literature","volume":"70","author":"Chen Cardenas","year":"2020","journal-title":"Endocrine"},{"issue":"6","key":"2024010407204523200_bnad026-B143","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1530\/EJE-20-0532","article-title":"Functional imaging with 11C-metomidate PET for subtype diagnosis in primary aldosteronism","volume":"183","author":"Soinio","year":"2020","journal-title":"Eur J Endocrinol"},{"issue":"1","key":"2024010407204523200_bnad026-B144","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1038\/s41591-022-02114-5","article-title":"[11C]metomidate PET-CT versus adrenal vein sampling for diagnosing surgically curable primary aldosteronism: a prospective, within-patient trial","volume":"29","author":"Wu","year":"2023","journal-title":"Nat Med"},{"issue":"11","key":"2024010407204523200_bnad026-B145","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1097\/RLU.0000000000004369","article-title":"Predicting treatment response in primary aldosteronism using 11C-metomidate positron emission tomography","volume":"47","author":"Lu","year":"2022","journal-title":"Clin Nucl Med"},{"issue":"6","key":"2024010407204523200_bnad026-B146","doi-asserted-by":"crossref","first-page":"e368","DOI":"10.1002\/edm2.368","article-title":"Lateralization in 11C-metomidate PET and outcome of adrenalectomy in primary aldosteronism","volume":"5","author":"Isoj\u00e4rvi","year":"2022","journal-title":"Endocrinol Diabetes Metab"},{"issue":"2","key":"2024010407204523200_bnad026-B147","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1007\/s00259-022-05957-9","article-title":"First-in-human evaluation of [18F] CETO: a novel tracer for adrenocortical tumours","volume":"50","author":"Silins","year":"2022","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"2","key":"2024010407204523200_bnad026-B148","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1007\/s00330-022-09058-x","article-title":"Functional nodules in primary aldosteronism: identification of CXCR4 expression with 68Ga-pentixafor PET\/CT","volume":"33","author":"Gao","year":"2022","journal-title":"Eur Radiol"},{"issue":"11","key":"2024010407204523200_bnad026-B149","doi-asserted-by":"crossref","first-page":"2656","DOI":"10.1007\/s00259-020-04722-0","article-title":"Imaging CXCR4 expression in patients with suspected primary hyperaldosteronism","volume":"47","author":"Ding","year":"2020","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"2","key":"2024010407204523200_bnad026-B150","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1161\/HYPERTENSIONAHA.117.09975","article-title":"Targeting CXCR4 (CXC chemokine receptor type 4) for molecular imaging of aldosterone-producing adenoma","volume":"71","author":"Heinze","year":"2018","journal-title":"Hypertension"},{"issue":"10","key":"2024010407204523200_bnad026-B151","doi-asserted-by":"crossref","first-page":"2187","DOI":"10.7150\/ijms.51206","article-title":"Para-chloro-2-[18F] fluoroethyl-etomidate: a promising new PET radiotracer for adrenocortical imaging","volume":"18","author":"Silins","year":"2021","journal-title":"Int J Med Sci"},{"issue":"3","key":"2024010407204523200_bnad026-B152","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1210\/jc.2015-3431","article-title":"A novel CYP11B2-specific imaging agent for detection of unilateral subtypes of primary aldosteronism","volume":"101","author":"Abe","year":"2016","journal-title":"J Clin Endocrinol Metab"},{"key":"2024010407204523200_bnad026-B153","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.nucmedbio.2018.11.002","article-title":"Development of [18F] FAMTO: a novel fluorine-18 labelled positron emission tomography (PET) radiotracer for imaging CYP11B1 and CYP11B2 enzymes in adrenal glands","volume":"68","author":"Bongarzone","year":"2019","journal-title":"Nucl Med Biol"},{"issue":"5","key":"2024010407204523200_bnad026-B154","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1021\/acsmedchemlett.5b00054","article-title":"Discovery of benzimidazole CYP11B2 inhibitors with in vivo activity in rhesus monkeys","volume":"6","author":"Hoyt","year":"2015","journal-title":"ACS Med Chem Lett"},{"issue":"13","key":"2024010407204523200_bnad026-B155","doi-asserted-by":"crossref","first-page":"9321","DOI":"10.1021\/acs.jmedchem.1c00539","article-title":"Development of [18F] AldoView as the first highly selective aldosterone synthase PET tracer for imaging of primary hyperaldosteronism","volume":"64","author":"Sander","year":"2021","journal-title":"J Med Chem"},{"issue":"8","key":"2024010407204523200_bnad026-B156","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1097\/RLU.0000000000004244","article-title":"Usefulness of 68Ga-pentixafor PET\/CT on diagnosis and management of Cushing syndrome","volume":"47","author":"Ding","year":"2022","journal-title":"Clin Nucl Med"},{"issue":"2","key":"2024010407204523200_bnad026-B157","doi-asserted-by":"crossref","first-page":"e2255609","DOI":"10.1001\/jamanetworkopen.2022.55609","article-title":"Accuracy of gallium-68 pentixafor positron emission tomography-computed tomography for subtyping diagnosis of primary aldosteronism","volume":"6","author":"Hu","year":"2023","journal-title":"JAMA Network Open"},{"issue":"8","key":"2024010407204523200_bnad026-B158","doi-asserted-by":"crossref","first-page":"e060779","DOI":"10.1136\/bmjopen-2022-060779","article-title":"Protocol: CXCR4-directed [68Ga] Ga-PentixaFor PET\/CT versus adrenal vein sampling performance: a study protocol for a randomised two-step controlled diagnoStic Trial Ultimately comparing hypertenSion outcome in primary aldosteronism (CASTUS)","volume":"12","author":"Chaman Baz","year":"2022","journal-title":"BMJ Open"},{"issue":"1","key":"2024010407204523200_bnad026-B159","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13244-020-00887-2","article-title":"Radiomics in medical imaging\u2014\u201chow-to\u201d guide and critical reflection","volume":"11","author":"Van Timmeren","year":"2020","journal-title":"Insights Imaging"},{"issue":"4","key":"2024010407204523200_bnad026-B160","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1007\/s13167-018-0149-3","article-title":"Radiomics improves efficiency for differentiating subclinical pheochromocytoma from lipid-poor adenoma: a predictive, preventive and personalized medical approach in adrenal incidentalomas","volume":"9","author":"Yi","year":"2018","journal-title":"EPMA J"},{"issue":"3","key":"2024010407204523200_bnad026-B161","doi-asserted-by":"crossref","first-page":"208","DOI":"10.5152\/dir.2022.21691","article-title":"Differentiation of adrenal adenomas from adrenal metastases in single-phased staging dual-energy CT and radiomics","volume":"28","author":"Winkelmann","year":"2022","journal-title":"Diagn Interv Radiol"},{"issue":"1","key":"2024010407204523200_bnad026-B162","doi-asserted-by":"crossref","first-page":"zraa061","DOI":"10.1093\/bjsopen\/zraa061","article-title":"Radiomics: a new tool to differentiate adrenocortical adenoma from carcinoma","volume":"5","author":"Torresan","year":"2021","journal-title":"BJS Open"},{"issue":"3","key":"2024010407204523200_bnad026-B163","doi-asserted-by":"crossref","first-page":"578","DOI":"10.3390\/diagnostics12030578","article-title":"Radiomics in cross-sectional adrenal imaging: a systematic review and quality assessment study","volume":"12","author":"Stanzione","year":"2022","journal-title":"Diagnostics"},{"key":"2024010407204523200_bnad026-B164","doi-asserted-by":"crossref","first-page":"873189","DOI":"10.3389\/fendo.2022.873189","article-title":"Machine learning-based texture analysis in the characterization of cortisol secreting vs. Non-secreting adrenocortical incidentalomas in CT scan","volume":"13","author":"Maggio","year":"2022","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"3","key":"2024010407204523200_bnad026-B165","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1007\/s11845-022-03105-8","article-title":"A machine learning approach to distinguishing between non-functioning and autonomous cortisol secreting adrenal incidentaloma on magnetic resonance imaging using texture analysis","volume":"192","author":"Piskin","year":"2022","journal-title":"Ir J Med Sci"},{"issue":"1","key":"2024010407204523200_bnad026-B166","first-page":"1","article-title":"Radiomics utilization to differentiate nonfunctional adenoma in essential hypertension and functional adenoma in primary aldosteronism","volume":"12","author":"Chen","year":"2022","journal-title":"Sci Rep"},{"key":"2024010407204523200_bnad026-B167","doi-asserted-by":"crossref","first-page":"634879","DOI":"10.3389\/fonc.2021.634879","article-title":"A clinical-radiomic nomogram based on unenhanced computed tomography for predicting the risk of aldosterone-producing adenoma","volume":"11","author":"He","year":"2021","journal-title":"Front Oncol"},{"issue":"3","key":"2024010407204523200_bnad026-B168","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1210\/jc.2003-031337","article-title":"Increased diagnosis of primary aldosteronism, including surgically correctable forms, in centers from five continents","volume":"89","author":"Mulatero","year":"2004","journal-title":"J Clin Endocrinol Metab"},{"issue":"6","key":"2024010407204523200_bnad026-B169","doi-asserted-by":"crossref","first-page":"1775","DOI":"10.1016\/S0022-5347(01)67303-8","article-title":"Therapeutic outcome of primary aldosteronism: adrenalectomy versus enucleation of aldosterone-producing adenoma","volume":"153","author":"Nakada","year":"1995","journal-title":"J Urol"},{"issue":"11","key":"2024010407204523200_bnad026-B170","doi-asserted-by":"crossref","first-page":"3965","DOI":"10.1210\/jc.2012-2234","article-title":"Prolonged zona glomerulosa insufficiency causing hyperkalemia in primary aldosteronism after adrenalectomy","volume":"97","author":"Fischer","year":"2012","journal-title":"J Clin Endocrinol Metab"},{"issue":"5","key":"2024010407204523200_bnad026-B171","doi-asserted-by":"crossref","first-page":"1578","DOI":"10.1016\/j.juro.2010.12.051","article-title":"Long-term results of a prospective, randomized trial comparing retroperitoneoscopic partial versus total adrenalectomy for aldosterone producing adenoma","volume":"185","author":"Fu","year":"2011","journal-title":"J Urol"},{"issue":"6","key":"2024010407204523200_bnad026-B172","doi-asserted-by":"crossref","first-page":"1418","DOI":"10.1016\/j.euf.2020.06.023","article-title":"Minimally invasive partial versus total adrenalectomy for the treatment of primary aldosteronism: results of a multicenter series according to the PASO criteria","volume":"7","author":"Anceschi","year":"2021","journal-title":"Eur Urol Focus"},{"issue":"5","key":"2024010407204523200_bnad026-B173","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.3390\/jcm11051263","article-title":"Minimally invasive partial vs. total adrenalectomy for the treatment of unilateral primary aldosteronism: a systematic review and meta-analysis","volume":"11","author":"Flammia","year":"2022","journal-title":"J Clin Med"},{"issue":"1","key":"2024010407204523200_bnad026-B174","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/S0090-4295(02)02240-9","article-title":"Laparoscopic partial adrenalectomy in patients with aldosterone-producing adenomas: indications, technique, and results","volume":"61","author":"Jeschke","year":"2003","journal-title":"Urology"},{"issue":"1","key":"2024010407204523200_bnad026-B175","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.jamcollsurg.2011.03.007","article-title":"Primary aldosteronism: results of adrenalectomy for nonsingle adenoma","volume":"213","author":"Quillo","year":"2011","journal-title":"J Am Coll Surg"},{"issue":"2","key":"2024010407204523200_bnad026-B176","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1097\/JU.0000000000001752","article-title":"Partial adrenalectomy carries a considerable risk of incomplete cure in primary aldosteronism","volume":"206","author":"van de Wiel","year":"2021","journal-title":"J Urol"},{"key":"2024010407204523200_bnad026-B177","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/j.mce.2015.04.022","article-title":"Immunohistochemical, genetic and clinical characterization of sporadic aldosterone-producing adenomas","volume":"411","author":"Monticone","year":"2015","journal-title":"Mol Cell Endocrinol"},{"issue":"7","key":"2024010407204523200_bnad026-B178","doi-asserted-by":"crossref","first-page":"E1341","DOI":"10.1210\/jc.2013-4255","article-title":"Adrenal nodularity and somatic mutations in primary aldosteronism: one node is the culprit?","volume":"99","author":"Dekkers","year":"2014","journal-title":"J Clin Endocrinol Metab"},{"issue":"5","key":"2024010407204523200_bnad026-B179","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1016\/j.eururo.2018.07.030","article-title":"Robot-assisted partial adrenalectomy for the treatment of Conn's syndrome: surgical technique, and perioperative and functional outcomes","volume":"75","author":"Simone","year":"2019","journal-title":"Eur Urol"},{"issue":"5","key":"2024010407204523200_bnad026-B180","doi-asserted-by":"crossref","first-page":"388","DOI":"10.5603\/EP.a2020.0033","article-title":"Adrenal-sparing surgery for a hormonally active tumour\u2014a single-centre experience","volume":"71","author":"Toutounchi","year":"2020","journal-title":"Endokrynol Pol"},{"issue":"1","key":"2024010407204523200_bnad026-B181","first-page":"38","article-title":"Cortex sparing laparoscopic adrenalectomy in a patient with Conn's syndrome","volume":"29","author":"Yeti\u015fir","year":"2013","journal-title":"Ulus Cerrahi Derg"},{"issue":"2","key":"2024010407204523200_bnad026-B182","doi-asserted-by":"crossref","first-page":"103","DOI":"10.22465\/kjuo.2019.17.2.103","article-title":"Laparoscopic partial adrenalectomy: surgical technique and outcome","volume":"17","author":"Ko","year":"2019","journal-title":"Korean J Urol Oncol"},{"issue":"9","key":"2024010407204523200_bnad026-B183","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1111\/j.1464-410X.2009.08523.x","article-title":"Laparoscopic simultaneous bilateral partial and total adrenalectomy: a longer follow-up","volume":"104","author":"Liao","year":"2009","journal-title":"BJU Int"},{"issue":"1","key":"2024010407204523200_bnad026-B184","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1007\/s00464-001-8127-5","article-title":"Laparoscopic adrenal-sparing surgery for primary hyperaldosteronism due to aldosterone-producing adenoma","volume":"16","author":"Kok","year":"2002","journal-title":"Surg Endosc"},{"issue":"7","key":"2024010407204523200_bnad026-B185","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1016\/j.jvir.2016.03.042","article-title":"Clinical outcomes following percutaneous radiofrequency ablation of unilateral aldosterone-producing adenoma: comparison with adrenalectomy","volume":"27","author":"Sarwar","year":"2016","journal-title":"J Vasc Interv Radiol"},{"issue":"10","key":"2024010407204523200_bnad026-B186","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1089\/end.2013.0635","article-title":"Retroperitoneoscopic-guided cool-tip radiofrequency ablation of adrenocortical aldosteronoma","volume":"28","author":"Yang","year":"2014","journal-title":"J Endourol"},{"issue":"2","key":"2024010407204523200_bnad026-B187","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1148\/radiol.10081634","article-title":"Principles of and advances in percutaneous ablation","volume":"258","author":"Ahmed","year":"2011","journal-title":"Radiology"},{"issue":"3","key":"2024010407204523200_bnad026-B188","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1097\/MED.0000000000000627","article-title":"Thermal ablation in adrenal disorders: a discussion of the technology, the clinical evidence and the future","volume":"28","author":"Donlon","year":"2021","journal-title":"Curr Opin Endocrinol Diabetes Obes"},{"issue":"4","key":"2024010407204523200_bnad026-B189","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.1007\/s13304-021-01069-5","article-title":"Comparison of the radiofrequency ablation versus laparoscopic adrenalectomy for aldosterone-producing adenoma: a meta-analysis of perioperative outcomes and safety","volume":"73","author":"Guo","year":"2021","journal-title":"Updates Surg"},{"issue":"6","key":"2024010407204523200_bnad026-B190","doi-asserted-by":"crossref","first-page":"2795","DOI":"10.1007\/s00261-020-02887-8","article-title":"Ablation versus laparoscopic adrenalectomy for the treatment of aldosterone\u2013producing adenoma: a meta-analysis","volume":"46","author":"Chen","year":"2021","journal-title":"Abdom Radiol (NY)"},{"issue":"1","key":"2024010407204523200_bnad026-B191","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12876-020-01553-z","article-title":"Clinical outcomes of surgical resection versus radiofrequency ablation in very-early-stage hepatocellular carcinoma: a propensity score matching analysis","volume":"21","author":"Li","year":"2021","journal-title":"BMC Gastroenterol"},{"issue":"1","key":"2024010407204523200_bnad026-B192","doi-asserted-by":"crossref","first-page":"1639","DOI":"10.1080\/02656736.2021.1983037","article-title":"Review of clinical tumor ablation advance in Asia","volume":"38","author":"Wang","year":"2021","journal-title":"Int J Hyperthermia"},{"issue":"1","key":"2024010407204523200_bnad026-B193","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41598-022-18136-5","article-title":"Safety and feasibility of radiofrequency ablation using bipolar electrodes for aldosterone-producing adenoma: a multicentric prospective clinical study","volume":"12","author":"Oguro","year":"2022","journal-title":"Sci Rep"},{"issue":"3","key":"2024010407204523200_bnad026-B194","doi-asserted-by":"crossref","first-page":"1970","DOI":"10.1007\/s00464-021-08481-3","article-title":"Laparoscopic adrenalectomy vs. Radiofrequency ablation for the treatment of primary aldosteronism. A single center retrospective cohort analysis adjusted with propensity score","volume":"36","author":"Cano-Valderrama","year":"2021","journal-title":"Surg Endosc"},{"issue":"7","key":"2024010407204523200_bnad026-B195","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1161\/CIRCULATIONAHA.121.054318","article-title":"Catheter-Based adrenal ablation remits primary aldosteronism: a randomized medication-controlled trial","volume":"144","author":"Zhao","year":"2021","journal-title":"Circulation"},{"issue":"4","key":"2024010407204523200_bnad026-B196","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1097\/HJH.0000000000002708","article-title":"Radiofrequency ablation for adenoma in patients with primary aldosteronism and hypertension: ADERADHTA, a pilot study","volume":"39","author":"Bouhanick","year":"2021","journal-title":"J Hypertens"},{"issue":"2","key":"2024010407204523200_bnad026-B197","first-page":"160","article-title":"Immediate results and long-term outcomes following percutaneous radiofrequency ablation of unilateral aldosterone-producing adenoma","volume":"36","author":"Lo","year":"2020","journal-title":"Acta Cardiologica Sinica"},{"issue":"2","key":"2024010407204523200_bnad026-B198","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1148\/radiol.2016152277","article-title":"Aldosterone-producing adenoma in primary aldosteronism: CT-guided radiofrequency ablation\u2014long-term results and recurrence rate","volume":"281","author":"Liu","year":"2016","journal-title":"Radiology"},{"key":"2024010407204523200_bnad026-B199","doi-asserted-by":"crossref","first-page":"bcr2013009692","DOI":"10.1136\/bcr-2013-009692","article-title":"Percutaneous ablation of functioning adenoma in a patient with a single adrenal gland","volume":"2013","author":"Nunes","year":"2013","journal-title":"BMJ Case Rep"},{"issue":"9","key":"2024010407204523200_bnad026-B200","doi-asserted-by":"crossref","first-page":"1618","DOI":"10.1111\/jch.13960","article-title":"Adrenal artery ablation for primary aldosteronism without apparent aldosteronoma: an efficacy and safety, proof-of-principle trial","volume":"22","author":"Zhang","year":"2020","journal-title":"J Clin Hypertens (Greenwich)"},{"key":"2024010407204523200_bnad026-B201","doi-asserted-by":"crossref","first-page":"1013426","DOI":"10.3389\/fcvm.2022.1013426","article-title":"Case report: percutaneous adrenal arterial embolization cures resistant hypertension","volume":"9","author":"Zhou","year":"2022","journal-title":"Front Cardiovasc Med"},{"issue":"1","key":"2024010407204523200_bnad026-B202","doi-asserted-by":"crossref","first-page":"190","DOI":"10.2214\/AJR.12.9507","article-title":"Adrenal artery embolization: anatomy, indications, and technical considerations","volume":"201","author":"Fowler","year":"2013","journal-title":"Am J Roentgenol"},{"issue":"1","key":"2024010407204523200_bnad026-B203","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1080\/02656736.2022.2125590","article-title":"Image-based computer modeling assessment of microwave ablation for treatment of adrenal tumors","volume":"39","author":"Sebek","year":"2022","journal-title":"Int J Hyperthermia"},{"issue":"3","key":"2024010407204523200_bnad026-B204","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1067\/j.cpradiol.2007.10.001","article-title":"Radiofrequency and microwave ablation of the liver, lung, kidney, and bone: what are the differences?","volume":"38","author":"Brace","year":"2009","journal-title":"Curr Probl Diagn Radiol"},{"issue":"7","key":"2024010407204523200_bnad026-B205","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.1016\/j.jvir.2020.01.016","article-title":"Directional microwave ablation: experimental evaluation of a 2.45-GHz applicator in ex vivo and in vivo liver","volume":"31","author":"Pfannenstiel","year":"2020","journal-title":"J Vasc Interv Radiol"},{"key":"2024010407204523200_bnad026-B206","doi-asserted-by":"crossref","first-page":"102753","DOI":"10.1016\/j.cis.2022.102753","article-title":"Photothermal conversion and transfer in photothermal therapy: from macroscale to nanoscale","volume":"308","author":"Ren","year":"2022","journal-title":"Adv Colloid Interface Sci"},{"issue":"16","key":"2024010407204523200_bnad026-B207","doi-asserted-by":"crossref","first-page":"2768","DOI":"10.3390\/nano12162768","article-title":"Current challenges in image-guided magnetic hyperthermia therapy for liver cancer","volume":"12","author":"Sharma","year":"2022","journal-title":"Nanomaterials"},{"issue":"1","key":"2024010407204523200_bnad026-B208","doi-asserted-by":"crossref","first-page":"1362","DOI":"10.1080\/02656736.2020.1857445","article-title":"Can accurate evaluation of the treatment success after radiofrequency ablation of liver tumors be achieved by visual inspection alone? Results of a blinded assessment with 38 interventional oncologists","volume":"37","author":"Laimer","year":"2020","journal-title":"Int J Hyperthermia"},{"issue":"8","key":"2024010407204523200_bnad026-B209","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1161\/CIRCULATIONAHA.118.033597","article-title":"Primary aldosteronism: practical approach to diagnosis and management","volume":"138","author":"Byrd","year":"2018","journal-title":"Circulation"},{"issue":"1","key":"2024010407204523200_bnad026-B210","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1507\/endocrj.EJ13-0353","article-title":"Prognosis of primary aldosteronism in Japan: results from a nationwide epidemiological study","volume":"61","author":"Miyake","year":"2013","journal-title":"Endocr J"},{"issue":"10","key":"2024010407204523200_bnad026-B211","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1038\/ajh.2008.243","article-title":"Adrenalectomy improves arterial stiffness in primary aldosteronism","volume":"21","author":"\u0160trauch","year":"2008","journal-title":"Am J Hypertens"},{"issue":"4","key":"2024010407204523200_bnad026-B212","doi-asserted-by":"crossref","first-page":"400","DOI":"10.4158\/EP14512.RA","article-title":"Genetics of primary aldosteronism","volume":"21","author":"Vaidya","year":"2015","journal-title":"Endocr Pract"},{"issue":"5","key":"2024010407204523200_bnad026-B213","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1097\/HJH.0b013e3283455ca5","article-title":"A double-blind, randomized study comparing the antihypertensive effect of eplerenone and spironolactone in patients with hypertension and evidence of primary aldosteronism","volume":"29","author":"Parthasarathy","year":"2011","journal-title":"J Hypertens"},{"issue":"19","key":"2024010407204523200_bnad026-B214","doi-asserted-by":"crossref","first-page":"2512","DOI":"10.1161\/01.CIR.0000071081.35693.9A","article-title":"Eplerenone: cardiovascular protection","volume":"107","author":"Brown","year":"2003","journal-title":"Circulation"},{"issue":"5","key":"2024010407204523200_bnad026-B215","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1161\/hy1101.095010","article-title":"Blood pressure responses to small doses of amiloride and spironolactone in normotensive subjects","volume":"38","author":"Pratt","year":"2001","journal-title":"Hypertension"},{"issue":"1","key":"2024010407204523200_bnad026-B216","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1038\/clpt.1982.9","article-title":"Amiloride in primary hyperaldosteronism","volume":"31","author":"Gritting","year":"1982","journal-title":"Clin Pharmacol Ther"},{"issue":"5","key":"2024010407204523200_bnad026-B217","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1136\/heart.88.5.475","article-title":"Increasing plasma potassium with amiloride shortens the QT interval and reduces ventricular extrasystoles but does not change endothelial function or heart rate variability in chronic heart failure","volume":"88","author":"Farquharson","year":"2002","journal-title":"Heart"},{"key":"2024010407204523200_bnad026-B218","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1016\/j.ejphar.2015.06.015","article-title":"Pharmacological profile of CS-3150, a novel, highly potent and selective non-steroidal mineralocorticoid receptor antagonist","volume":"761","author":"Arai","year":"2015","journal-title":"Eur J Pharmacol"},{"issue":"1","key":"2024010407204523200_bnad026-B219","doi-asserted-by":"crossref","first-page":"T125","DOI":"10.1530\/JOE-16-0600","article-title":"30 Years of the mineralocorticoid receptor: mineralocorticoid receptor antagonists: 60 years of research and development","volume":"234","author":"Kolkhof","year":"2017","journal-title":"J Endocrinol"},{"issue":"4","key":"2024010407204523200_bnad026-B220","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1038\/s41440-020-00570-5","article-title":"Efficacy and safety of esaxerenone (CS-3150), a newly available nonsteroidal mineralocorticoid receptor blocker, in hypertensive patients with primary aldosteronism","volume":"44","author":"Satoh","year":"2021","journal-title":"Hypertens Res"},{"issue":"12","key":"2024010407204523200_bnad026-B221","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1080\/00498254.2016.1263766","article-title":"Pharmacokinetics, distribution, and disposition of esaxerenone, a novel, highly potent and selective non-steroidal mineralocorticoid receptor antagonist, in rats and monkeys","volume":"47","author":"Yamada","year":"2017","journal-title":"Xenobiotica"},{"issue":"1","key":"2024010407204523200_bnad026-B222","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1161\/HYPERTENSIONAHA.119.13569","article-title":"Double-blind randomized phase 3 study comparing esaxerenone (CS-3150) and eplerenone in patients with essential hypertension (ESAX-HTN study)","volume":"75","author":"Ito","year":"2020","journal-title":"Hypertension"},{"issue":"8","key":"2024010407204523200_bnad026-B223","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.2215\/CJN.14751218","article-title":"Efficacy and safety of esaxerenone (CS-3150) for the treatment of type 2 diabetes with microalbuminuria: a randomized, double-blind, placebo-controlled, phase II trial","volume":"14","author":"Ito","year":"2019","journal-title":"Clin J Am Soc Nephrol"},{"issue":"12","key":"2024010407204523200_bnad026-B224","doi-asserted-by":"crossref","first-page":"1932","DOI":"10.1038\/s41440-019-0314-7","article-title":"Long-term phase 3 study of esaxerenone as mono or combination therapy with other antihypertensive drugs in patients with essential hypertension","volume":"42","author":"Rakugi","year":"2019","journal-title":"Hypertens Res"},{"issue":"23","key":"2024010407204523200_bnad026-B225","doi-asserted-by":"crossref","first-page":"2219","DOI":"10.1056\/NEJMoa2025845","article-title":"Effect of finerenone on chronic kidney disease outcomes in type 2 diabetes","volume":"383","author":"Bakris","year":"2020","journal-title":"N Engl J Med"},{"issue":"24","key":"2024010407204523200_bnad026-B226","doi-asserted-by":"crossref","first-page":"2252","DOI":"10.1056\/NEJMoa2110956","article-title":"Cardiovascular events with finerenone in kidney disease and type 2 diabetes","volume":"385","author":"Pitt","year":"2021","journal-title":"N Engl J Med"},{"issue":"1","key":"2024010407204523200_bnad026-B227","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1002\/ejhf.444","article-title":"Non-steroidal mineralocorticoid receptor antagonism for the treatment of cardiovascular and renal disease","volume":"18","author":"Bramlage","year":"2016","journal-title":"Eur J Heart Fail"},{"issue":"36","key":"2024010407204523200_bnad026-B228","doi-asserted-by":"crossref","first-page":"21876","DOI":"10.1074\/jbc.M115.657957","article-title":"Finerenone impedes aldosterone-dependent nuclear import of the mineralocorticoid receptor and prevents genomic recruitment of steroid receptor coactivator-1","volume":"290","author":"Amazit","year":"2015","journal-title":"J Biol Chem"},{"issue":"31","key":"2024010407204523200_bnad026-B229","doi-asserted-by":"crossref","first-page":"2453","DOI":"10.1093\/eurheartj\/eht187","article-title":"Safety and tolerability of the novel non-steroidal mineralocorticoid receptor antagonist BAY 94-8862 in patients with chronic heart failure and mild or moderate chronic kidney disease: a randomized, double-blind trial","volume":"34","author":"Pitt","year":"2013","journal-title":"Eur Heart J"},{"issue":"4","key":"2024010407204523200_bnad026-B230","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1002\/cpdd.855","article-title":"Phase 1 studies to define the safety, tolerability, and pharmacokinetic and pharmacodynamic profiles of the nonsteroidal mineralocorticoid receptor antagonist apararenone in healthy volunteers","volume":"10","author":"Nakamura","year":"2021","journal-title":"Clin Pharmacol Drug Dev"},{"issue":"2","key":"2024010407204523200_bnad026-B231","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1007\/s10157-020-01963-z","article-title":"Apararenone in patients with diabetic nephropathy: results of a randomized, double-blind, placebo-controlled phase 2 dose-response study and open-label extension study","volume":"25","author":"Wada","year":"2021","journal-title":"Clin Exp Nephrol"},{"issue":"3","key":"2024010407204523200_bnad026-B232","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1124\/dmd.118.084897","article-title":"Pharmacokinetics, metabolism, and excretion of [14C] esaxerenone, a novel mineralocorticoid receptor blocker in humans","volume":"47","author":"Yamada","year":"2019","journal-title":"Drug Metab Dispos"},{"issue":"12","key":"2024010407204523200_bnad026-B233","doi-asserted-by":"crossref","first-page":"1715","DOI":"10.2215\/CJN.06870520","article-title":"Esaxerenone (CS-3150) in patients with type 2 diabetes and microalbuminuria (ESAX-DN): phase 3 randomized controlled clinical trial","volume":"15","author":"Ito","year":"2020","journal-title":"Clin J Am Soc Nephrol"},{"key":"2024010407204523200_bnad026-B234"},{"key":"2024010407204523200_bnad026-B235"},{"issue":"2","key":"2024010407204523200_bnad026-B236","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1111\/fcp.12170","article-title":"Pharmacokinetics, safety and tolerability of the novel, selective mineralocorticoid receptor antagonist finerenone-results from first-in-man and relative bioavailability studies","volume":"30","author":"Lentini","year":"2016","journal-title":"Fundam Clin Pharmacol"},{"issue":"6","key":"2024010407204523200_bnad026-B237","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1007\/s13318-018-0483-9","article-title":"Pharmacokinetics of the novel, selective, non-steroidal mineralocorticoid receptor antagonist finerenone in healthy volunteers: results from an absolute bioavailability study and drug\u2013drug interaction studies in vitro and in vivo","volume":"43","author":"Heinig","year":"2018","journal-title":"Eur J Drug Metab Pharmacokinet"},{"issue":"6","key":"2024010407204523200_bnad026-B238","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1002\/jcph.865","article-title":"Population pharmacokinetics of LY2623091 in patients with hypertension and chronic kidney disease","volume":"57","author":"Wang","year":"2017","journal-title":"J Clin Pharmacol"},{"key":"2024010407204523200_bnad026-B239"},{"key":"2024010407204523200_bnad026-B240"},{"issue":"10","key":"2024010407204523200_bnad026-B241","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1080\/13543784.2021.1985462","article-title":"An evaluation of KBP-5074 in advanced chronic kidney disease with uncontrolled hypertension","volume":"30","author":"Pitt","year":"2021","journal-title":"Expert Opin Invest Drugs"},{"issue":"1","key":"2024010407204523200_bnad026-B242","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1161\/HYPERTENSIONAHA.121.17073","article-title":"Effect of KBP-5074 on blood pressure in advanced chronic kidney disease: results of the BLOCK-CKD study","volume":"78","author":"Bakris","year":"2021","journal-title":"Hypertension"},{"key":"2024010407204523200_bnad026-B243"},{"issue":"5","key":"2024010407204523200_bnad026-B244","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1007\/s40261-017-0497-0","article-title":"Drug interaction potential of osilodrostat (LCI699) based on its effect on the pharmacokinetics of probe drugs of cytochrome P450 enzymes in healthy adults","volume":"37","author":"Armani","year":"2017","journal-title":"Clin Drug Investig"},{"issue":"5","key":"2024010407204523200_bnad026-B245","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1161\/HYPERTENSIONAHA.110.157271","article-title":"Aldosterone synthase inhibition with LCI699: a proof-of-concept study in patients with primary aldosteronism","volume":"56","author":"Amar","year":"2010","journal-title":"Hypertension"},{"issue":"5","key":"2024010407204523200_bnad026-B246","doi-asserted-by":"crossref","first-page":"2971","DOI":"10.1210\/endo.130.5.1572304","article-title":"Zone-specific expression of aldosterone synthase cytochrome P-450 and cytochrome P-45011 beta in rat adrenal cortex: histochemical basis for the functional zonation","volume":"130","author":"Ogishima","year":"1992","journal-title":"Endocrinology"},{"issue":"12","key":"2024010407204523200_bnad026-B247","doi-asserted-by":"crossref","first-page":"1853","DOI":"10.1210\/mend-5-12-1853","article-title":"Different isozymes of mouse 11\/ss-hydroxylase produce mineralocorticoids and glucocorticoids","volume":"5","author":"Domalik","year":"1991","journal-title":"Mol Endocrinol"},{"key":"2024010407204523200_bnad026-B248","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/bs.vh.2018.10.002","article-title":"Inhibitors of aldosterone synthase","volume":"109","author":"Weldon","year":"2019","journal-title":"Vitam Horm"},{"issue":"3","key":"2024010407204523200_bnad026-B249","first-page":"571","article-title":"The effects of fadrozole hydrochloride on aldosterone secretion in healthy male subjects","volume":"74","author":"Trunet","year":"1992","journal-title":"J Clin Endocrinol Metab"},{"issue":"35","key":"2024010407204523200_bnad026-B250","doi-asserted-by":"crossref","first-page":"20961","DOI":"10.1016\/S0021-9258(19)30030-4","article-title":"Characterization of two genes encoding human steroid 11\u03b2-hydroxylase (P-45011\u03b2)","volume":"264","author":"Mornet","year":"1989","journal-title":"J Biol Chem"},{"issue":"18","key":"2024010407204523200_bnad026-B251","doi-asserted-by":"crossref","first-page":"1945","DOI":"10.1161\/CIRCULATIONAHA.111.029892","article-title":"Effects of a novel aldosterone synthase inhibitor for treatment of primary hypertension: results of a randomized, double-blind, placebo-and active-controlled phase 2 trial","volume":"124","author":"Calhoun","year":"2011","journal-title":"Circulation"},{"issue":"8","key":"2024010407204523200_bnad026-B252","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1177\/1060028020968808","article-title":"Osilodrostat: a novel steroidogenesis inhibitor to treat Cushing's disease","volume":"55","author":"Dougherty","year":"2021","journal-title":"Ann Pharmacother"},{"issue":"1","key":"2024010407204523200_bnad026-B253","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1161\/HYPERTENSIONAHA.116.07716","article-title":"Preclinical and early clinical profile of a highly selective and potent oral inhibitor of aldosterone synthase (CYP11B2)","volume":"69","author":"Bogman","year":"2017","journal-title":"Hypertension"},{"issue":"5","key":"2024010407204523200_bnad026-B254","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1056\/NEJMoa2213169","article-title":"Phase 2 trial of baxdrostat for treatment-resistant hypertension","volume":"388","author":"Freeman","year":"2023","journal-title":"N Engl J Med"},{"key":"2024010407204523200_bnad026-B255","doi-asserted-by":"crossref","first-page":"105332","DOI":"10.1016\/j.phrs.2020.105332","article-title":"Aldosterone synthase inhibitors for cardiovascular diseases: a comprehensive review of preclinical, clinical and in silico data","volume":"163","author":"Lenzini","year":"2021","journal-title":"Pharmacol Res"},{"issue":"4","key":"2024010407204523200_bnad026-B256","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1038\/ng.2550","article-title":"Somatic mutations in ATP1A1 and ATP2B3 lead to aldosterone-producing adenomas and secondary hypertension","volume":"45","author":"Beuschlein","year":"2013","journal-title":"Nat Genet"},{"issue":"6018","key":"2024010407204523200_bnad026-B257","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1126\/science.1198785","article-title":"K+ channel mutations in adrenal aldosterone-producing adenomas and hereditary hypertension","volume":"331","author":"Choi","year":"2011","journal-title":"Science"},{"issue":"3","key":"2024010407204523200_bnad026-B258","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1161\/HYPERTENSIONAHA.119.14349","article-title":"Somatic CACNA1H mutation as a cause of aldosterone-producing adenoma","volume":"75","author":"Nanba","year":"2020","journal-title":"Hypertension"},{"issue":"5","key":"2024010407204523200_bnad026-B259","doi-asserted-by":"crossref","first-page":"K37","DOI":"10.1530\/EJE-19-0377","article-title":"A somatic mutation in CLCN2 identified in a sporadic aldosterone-producing adenoma","volume":"181","author":"Dutta","year":"2019","journal-title":"Eur J Endocrinol"},{"issue":"5","key":"2024010407204523200_bnad026-B260","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1161\/HYPERTENSIONAHA.121.16498","article-title":"Genetics of primary aldosteronism","volume":"79","author":"Scholl","year":"2022","journal-title":"Hypertension"},{"issue":"6357","key":"2024010407204523200_bnad026-B261","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1038\/355262a0","article-title":"A chimaeric ll\u03b2-hydroxylase\/aldosterone synthase gene causes glucocorticoid-remediable aldosteronism and human hypertension","volume":"355","author":"LIfton","year":"1992","journal-title":"Nature"},{"issue":"3","key":"2024010407204523200_bnad026-B262","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1038\/s41588-018-0048-5","article-title":"CLCN2 Chloride channel mutations in familial hyperaldosteronism type II","volume":"50","author":"Scholl","year":"2018","journal-title":"Nat Genet"},{"issue":"8","key":"2024010407204523200_bnad026-B263","doi-asserted-by":"crossref","first-page":"3117","DOI":"10.1210\/jc.2008-0594","article-title":"A novel form of human mendelian hypertension featuring nonglucocorticoid-remediable aldosteronism","volume":"93","author":"Geller","year":"2008","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"2024010407204523200_bnad026-B264","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1161\/HYPERTENSIONAHA.111.183996","article-title":"KCNJ5 Mutations in European families with nonglucocorticoid remediable familial hyperaldosteronism","volume":"59","author":"Mulatero","year":"2012","journal-title":"Hypertension"},{"key":"2024010407204523200_bnad026-B265","doi-asserted-by":"crossref","first-page":"e06315","DOI":"10.7554\/eLife.06315","article-title":"Recurrent gain of function mutation in calcium channel CACNA1H causes early-onset hypertension with primary aldosteronism","volume":"4","author":"Scholl","year":"2015","journal-title":"elife"},{"issue":"7","key":"2024010407204523200_bnad026-B266","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1007\/s00424-020-02418-w","article-title":"De novo CACAN1D Ca2+ channelopathies: clinical phenotypes and molecular mechanism","volume":"472","author":"Ortner","year":"2020","journal-title":"Pfl\u00fcgers Arch"},{"issue":"12","key":"2024010407204523200_bnad026-B267","doi-asserted-by":"crossref","first-page":"49","DOI":"10.17116\/jnevro201811812149","article-title":"The third case report a patient with primary aldosteronism, seizures, and neurologic abnormalities (PASNA) syndrome de novo variant mutations in the CACNA1D gene","volume":"118","author":"Semenova","year":"2018","journal-title":"Zh Nevrol Psikhiatr Im S S Korsakova"},{"issue":"4","key":"2024010407204523200_bnad026-B268","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1111\/pedi.12512","article-title":"A CACNA1D mutation in a patient with persistent hyperinsulinaemic hypoglycaemia, heart defects, and severe hypotonia","volume":"18","author":"Flanagan","year":"2017","journal-title":"Pediatr Diabetes"},{"issue":"4","key":"2024010407204523200_bnad026-B269","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1161\/HYPERTENSIONAHA.118.11086","article-title":"Cellular and genetic causes of idiopathic hyperaldosteronism","volume":"72","author":"Omata","year":"2018","journal-title":"Hypertension"},{"issue":"11","key":"2024010407204523200_bnad026-B270","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s12276-019-0337-9","article-title":"Genetic causes of primary aldosteronism","volume":"51","author":"Seidel","year":"2019","journal-title":"Exp Mol Med"},{"key":"2024010407204523200_bnad026-B271","doi-asserted-by":"crossref","first-page":"132","DOI":"10.3389\/fendo.2021.631848","article-title":"Functional characteristic and significance of aldosterone-producing cell clusters in primary aldosteronism and age-related hypertension","volume":"12","author":"Pauzi","year":"2021","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"9","key":"2024010407204523200_bnad026-B272","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1038\/ng.2695","article-title":"Somatic and germline CACNA1D calcium channel mutations in aldosterone-producing adenomas and primary aldosteronism","volume":"45","author":"Scholl","year":"2013","journal-title":"Nat Genet"},{"issue":"9","key":"2024010407204523200_bnad026-B273","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1038\/ng.2716","article-title":"Somatic mutations in ATP1A1 and CACNA1D underlie a common subtype of adrenal hypertension","volume":"45","author":"Azizan","year":"2013","journal-title":"Nat Genet"},{"issue":"12","key":"2024010407204523200_bnad026-B274","doi-asserted-by":"crossref","first-page":"4582","DOI":"10.1210\/en.2015-1466","article-title":"Pathogenesis of adrenal aldosterone-producing adenomas carrying mutations of the Na+\/K+-ATPase","volume":"156","author":"Stindl","year":"2015","journal-title":"Endocrinology"},{"issue":"2","key":"2024010407204523200_bnad026-B275","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1038\/nrendo.2012.230","article-title":"Role of KCNJ5 in familial and sporadic primary aldosteronism","volume":"9","author":"Mulatero","year":"2013","journal-title":"Nat Rev Endocrinol"},{"issue":"7","key":"2024010407204523200_bnad026-B276","doi-asserted-by":"crossref","first-page":"2739","DOI":"10.1172\/JCI91733","article-title":"Macrolides selectively inhibit mutant KCNJ5 potassium channels that cause aldosterone-producing adenoma","volume":"127","author":"Scholl","year":"2017","journal-title":"J Clin Invest"},{"issue":"6","key":"2024010407204523200_bnad026-B277","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1016\/j.jash.2015.04.004","article-title":"Comparison of Morisky medication adherence scale with therapeutic drug monitoring in apparent treatment\u2013resistant hypertension","volume":"9","author":"Pandey","year":"2015","journal-title":"J Am Soc Hypertens"},{"issue":"7","key":"2024010407204523200_bnad026-B278","doi-asserted-by":"crossref","first-page":"1948","DOI":"10.1111\/bcp.15292","article-title":"Major disparities in patient-reported adherence compared to objective assessment of adherence using mass spectrometry: a prospective study in a tertiary-referral hypertension clinic","volume":"89","author":"Curneen","year":"2022","journal-title":"Br J Clin Pharmacol"},{"issue":"8","key":"2024010407204523200_bnad026-B279","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1016\/S0149-2918(01)80109-0","article-title":"A systematic review of the associations between dose regimens and medication compliance","volume":"23","author":"Claxton","year":"2001","journal-title":"Clin Ther"},{"issue":"10","key":"2024010407204523200_bnad026-B280","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1517\/17425247.5.10.1077","article-title":"Thermo-responsive systems for controlled drug delivery","volume":"5","author":"Bikram","year":"2008","journal-title":"Expert Opin Drug Delivery"},{"issue":"1-2","key":"2024010407204523200_bnad026-B281","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.ijpharm.2007.07.026","article-title":"Injectable block copolymer hydrogels for sustained release of a PEGylated drug","volume":"348","author":"Yu","year":"2008","journal-title":"Int J Pharm"},{"issue":"7","key":"2024010407204523200_bnad026-B282","doi-asserted-by":"crossref","first-page":"2004213","DOI":"10.1002\/advs.202004213","article-title":"Nanostructured dense collagen-polyester composite hydrogels as amphiphilic platforms for drug delivery","volume":"8","author":"Wang","year":"2021","journal-title":"Adv Sci (Weinh)"},{"issue":"5","key":"2024010407204523200_bnad026-B283","doi-asserted-by":"crossref","first-page":"1469","DOI":"10.1208\/s12249-016-0621-0","article-title":"Development and optimisation of spironolactone nanoparticles for enhanced dissolution rates and stability","volume":"18","author":"Kelidari","year":"2017","journal-title":"AAPS PharmSciTech"},{"issue":"3","key":"2024010407204523200_bnad026-B284","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1081\/DDC-52182","article-title":"Nanosuspension formulations for low-soluble drugs: pharmacokinetic evaluation using spironolactone as model compound","volume":"31","author":"Langguth","year":"2005","journal-title":"Drug Dev Ind Pharm"},{"issue":"1","key":"2024010407204523200_bnad026-B285","doi-asserted-by":"crossref","first-page":"444","DOI":"10.3762\/bjnano.3.51","article-title":"Magnetic-Fe\/Fe3O4-nanoparticle-bound SN38 as carboxylesterase-cleavable prodrug for the delivery to tumors within monocytes\/macrophages","volume":"3","author":"Wang","year":"2012","journal-title":"Beilstein J Nanotechnol"}],"container-title":["Endocrine Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/edrv\/advance-article-pdf\/doi\/10.1210\/endrev\/bnad026\/51346865\/bnad026.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/edrv\/article-pdf\/45\/1\/125\/54996343\/bnad026.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/edrv\/article-pdf\/45\/1\/125\/54996343\/bnad026.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,4]],"date-time":"2024-01-04T07:23:53Z","timestamp":1704353033000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/edrv\/article\/45\/1\/125\/7240099"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8,9]]},"references-count":285,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,8,9]]},"published-print":{"date-parts":[[2024,1,4]]}},"URL":"https:\/\/doi.org\/10.1210\/endrev\/bnad026","relation":{},"ISSN":["0163-769X","1945-7189"],"issn-type":[{"value":"0163-769X","type":"print"},{"value":"1945-7189","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,2]]},"published":{"date-parts":[[2023,8,9]]}}}